UNSPSC 51434914: Bendroflumethiazide/nadolol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434914 Bendroflumethiazide/nadolol, a Commodity code, designates specific branded and generic pharmaceutical formulations for treating hypertension and cardiac conditions. State and local governments purchase these medications primarily through emergency medical services procurement, cooperative purchasing arrangements with state health agencies, and multistate pharmaceutical contracting vehicles that aggregate demand across dozens of jurisdictions. Recent solicitations show that state health departments, municipal fire rescue departments, and cooperative purchasing alliances are actively sourcing generic multi-source pharmaceuticals and branded compounds—including this class of antihypertensive and beta-blocker combinations—for emergency response, chronic disease management, and institutional pharmacy distribution. Issuing bodies range from individual city fire departments (such as Tampa Fire Rescue) to state health and human services commissions and regional cooperative purchasing organizations (such as MMCAP). The latter model consolidates procurement across multiple state and local members, distributing products through established wholesaler networks and capturing volume pricing leverage unavailable to single jurisdictions.

Geographic activity spans Florida, Texas, Minnesota, and Oregon based on recent opportunities, with MMCAP's multistate cooperative model covering a broader regional footprint. The City of Tampa's Purchasing Department posted an IFB (No. 26P00188) on April 24, 2026, seeking Advanced Life Support Medications including related compounds, with bid opening April 8, 2026 and an estimated contract value of $40,000.00; the contract includes a 5 percent SLBE bid discount and runs one year with two optional one-year renewals. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013) posted April 3, 2026, to explore vendor capabilities for direct-to-manufacturer prescription programs, though this remains exploratory rather than a formal purchase commitment. The Minnesota Department of Administration's MMCAP issued an RFP (No. S1070000015802) for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; evaluation weighted price competitiveness at 75 percent and requires vendors to maintain relationships with AmerisourceBergen (Cencora), Cardinal Health, or Morris & Dickson for product distribution.